Physician profile
Michael Cookson
NPI 1528142635
$132,047.17
in general payments reported to CMS, 2019-2025
25 companies · $4,730 in 2025
The $4,730 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $15K · 2021: $12K · 2022: $17K · 2023: $25K · 2024: $14K · 2025: $4,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Travel and Lodging: $5,140 · Food and Beverage: $1,970 · Honoraria: $1,825 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,450.50 |
| Travel and Lodging | $5,139.95 |
| Food and Beverage | $1,969.58 |
| Honoraria | $1,825.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
| Education | $107.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31,308.34 | 2019-2025 | |
| Astellas Pharma US INC | $30,252.07 | 2019-2025 | Xtandi |
| Pfizer INC. | $15,182.31 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $15,082.79 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Progenics Pharmaceuticals, INC. | $11,531.36 | 2022-2024 | Pylarify |
| Ferring Pharmaceuticals INC. | $6,957.87 | 2019-2024 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $6,566.72 | 2019-2023 | |
| Janssen Biotech, INC. | $5,456.41 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Myovant Sciences INC. | $4,600.00 | 2021 | |
| Janssen Global Services, LLC | $2,567.50 | 2023-2024 | Erleada |
| Provepharm INC. | $1,000.00 | 2023 | Bludigo |
| Urogen Pharma, INC. | $868.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $190.78 | 2023-2025 | Lynparza |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $99.31 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bluewind Medical | $67.35 | 2025 | Revi |
| Novartis Pharmaceuticals Corporation | $53.75 | 2024-2025 | |
| Immunitybio, INC. | $31.00 | 2025 | |
| Procept Biorobotics Corporation | $29.93 | 2025 | |
| Tolmar, INC. | $23.43 | 2024 | |
| Myriad Genetic Laboratories, INC. | $22.29 | 2025 | Prolaris |
| Tersera Therapeutics LLC | $17.08 | 2024 | Xermelo |
| Telix Pharmaceuticals | $13.82 | 2023 | Illuccix |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cookson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.